You searched for - Fennec Pharmaceuticals : Fennec Pharmaceuticals

FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS

Posted on March 13, 2019 (March 28, 2019) by cmdsonline

Initiated rolling New Drug Application to U.S. FDA for PEDMARKTM Secured $12. 5 million debt financing to support a potential commercial launch Strong financial position with $22.8 million in cash and no debt Targeted commercial launch in 2020 RESEARCH TRIANGLE PARK, N.C., March 13, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a […]

FENNEC PHARMACEUTICALS ANNOUNCES $12.5 MILLION DEBT FINANCING WITH BRIDGE BANK

Posted on February 4, 2019 (March 28, 2019) by cmdsonline

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS) to be administered by infusion) for the prevention of ototoxicity induced by cisplatin chemotherapy in pediatric patients with solid tumors, announced a $12.5 million senior debt facility with the Life […]

FENNEC PHARMACEUTICALS INITIATES ROLLING NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARK™

Posted on December 20, 2018 (March 28, 2019) by cmdsonline

PEDMARKTM is proposed to be indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumors. RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, following a pre-submission meeting with the oncology division of […]

FENNEC PHARMACEUTICALS ANNOUNCES SCIENTIFIC SYMPOSIUM ON OTOTOXICITY IN PEDIATRIC CANCER PATIENTS AT THE 50TH CONGRESS OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY (SIOP) 2018 MEETING

Posted on November 16, 2018 (March 28, 2019) by cmdsonline

RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that leading experts in pediatric oncology will review the current data and clinical recommendations for management […]

FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS

Posted on November 13, 2018 (March 28, 2019) by cmdsonline

Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTM Targeting US approval of PEDMARKTM in the second half of 2019 Strong financial position with $24.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation […]

FENNEC TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE ON OCTOBER 1, 2018 IN NEW YORK CITY

Posted on September 26, 2018 (March 28, 2019) by cmdsonline

RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Rosty Raykov, CEO of Fennec, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Monday, […]

Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results

Posted on August 13, 2018 (March 18, 2019) by cmdsonline

Publication of PEDMARKTM SIOPEL 6 Clinical Data in The New England Journal of Medicine Joined Russell 3000 Index Strong financial position with $25.6 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a […]

FENNEC PHARMACEUTICALS RECEIVES POSITIVE OPINION ON THE PEDIATRIC INVESTIGATION PLAN FROM EUROPEAN MEDICINES AGENCY FOR PEDMARK TM AND CONFIRMATION OF ELIGIBILITY FOR A PEDIATRIC USE MARKETING AUTHORIZATION

Posted on August 7, 2018 (March 18, 2019) by cmdsonline

Research Triangle Park, NC, August 7, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s pediatric investigation plan (PIP) for PEDMARK TM for the condition of the prevention of platinum-induced ototoxic hearing loss. The indication […]

Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine

Posted on June 21, 2018 (March 18, 2019) by cmdsonline

SIOPEL 6 met primary endpoint (p=0.002) 48% reduction in the incidence of hearing loss No evidence of tumor protection RESEARCH TRIANGLE PARK, N.C., June 21, 2018 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate (STS)), announced today a publication […]

Fennec Pharmaceuticals Set to Join Russell 3000 Index

Posted on June 11, 2018 (March 18, 2019) by cmdsonline

Research Triangle Park, NC, June 11, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today it is set to join the broad-market Russell 3000Ò Index at […]